Shenzhen Bigeye Whale Technology Co., Ltd. – Trademark Portfolio
Entity Type: 99
Shenzhen Bigeye Whale Technology Co., Ltd. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. Currently, 4 trademarks are registered. Notable registered marks include COLVYOM, ZENCLEX, ZHEN LU, and NICOVITO. The owner is based in Shenzhen.
Room 1006, Block B, Building 1, Ganfeng Technology Building, No. 993, Jiaxian Road, Xiangjiaotang Community, Bantian Subdistrict, Longgang District
Shenzhen 518000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Shenzhen Bigeye Whale Technology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Shenzhen Bigeye Whale Technology Co., Ltd. have?
Shenzhen Bigeye Whale Technology Co., Ltd. has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.
What trademark classes does Shenzhen Bigeye Whale Technology Co., Ltd. file in?
Shenzhen Bigeye Whale Technology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Shenzhen Bigeye Whale Technology Co., Ltd.'s most well-known trademarks?
Shenzhen Bigeye Whale Technology Co., Ltd.'s registered trademark portfolio includes well-known marks such as COLVYOM, ZENCLEX, ZHEN LU, and NICOVITO. These are among 4 currently registered trademarks in the portfolio.
What is Shenzhen Bigeye Whale Technology Co., Ltd.'s trademark registration success rate?
Shenzhen Bigeye Whale Technology Co., Ltd. has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.